• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    ALTIVIA Appoints Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager

    4/8/24 12:44:00 PM ET
    $DOW
    $PFE
    Major Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DOW alert in real time by email

    HOUSTON, April 8, 2024 /PRNewswire/ -- ALTIVIA today announced that it has named Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager.

    Scott Barnum, Director of Manufacturing

    Mr. Barnum will oversee the process management, quality, and operations of ALTIVIA's Specialty and Oxide Chemicals' units. Mr. Hale will lead the development and management of ALTIVIA's Corporate Engineering Department.

    "We look forward to welcoming both Scott and Dean as ALTIVIA furthers its investment in growth, sustainability, and world-class operating performance," said Michael Jusbasche, ALTIVIA's Chief Executive Officer. "Their proven leadership and experience in the chemicals industry will fuel ALTIVIA's growth."

    Scott Barnum

    Mr. Barnum has 30 years of experience in the chemicals industry, including phosgenation, chlorination, sulfonation, and esterification processes. Prior to joining ALTIVIA, Mr. Barnum served as the Director of Manufacturing at Niacet Corporation, a division of Kerry Group, plc (OTC Markets KRYAY), an industry-leading manufacturer in food feed, and pharmaceutical additives. Mr. Barnum served as board member of the Buffalo Niagara Manufacturing Alliance, representing 194 member companies.

    During his career, Mr. Barnum has been recognized for his contributions to environmental, safety, and health management. Mr. Barnum holds a Bachelor of Science in Chemical Engineering from The State University of New York.

    Dean Hale

    Mr. Hale has spent the last 33 years in various engineering capacities in the chemicals industry, focused on process development, implementation, and optimization. He brings a breadth of industry experience in applications including petrochemicals, semiconductor chemicals, pharmaceuticals, and food additives. Prior to joining ALTIVIA, he most recently served as the Engineering Manager for Niacet Corporation, a division of Kerry Group, plc (OTC Markets: KRYAY), and has held various engineering and project management roles for DOW (NYSE:DOW) and Pfizer (NYSE:PFE).

    Mr. Hale has been a recipient of the Pfizer Innovation Award and the Teamwork Award, and Pharmacia's Outstanding Performance Recognition Award. Mr. Hale holds a Bachelor of Science in Chemical Engineering from Michigan State University and is certified as a Project Management Professional.

    Mr. Barnum's and Mr. Hale's leadership were instrumental in Niacet's winning the American Chemistry Council's (ACC) Company of the Year Award for outstanding environmental, safety, health, and security performance.

    About ALTIVIA

    Headquartered in Houston, Texas, privately held ALTIVIA was founded in 1986 and today operates four petrochemical and specialty chemical manufacturing facilities in Texas, Ohio, and West Virginia.

    • ALTIVIA Petrochemicals, with facilities in Haverhill, Ohio, is the third largest merchant producer of Phenol, Acetone, and alpha-methyl-styrene in the Americas.
    • ALTIVIA Specialty Chemicals, the largest producer of Phosgene derivative intermediates in the Americas, including chloroformates and acid chlorides, serving the pharmaceutical, organic peroxide, and agricultural markets from its operations in LaPorte, Texas.
    • ALTIVIA Ketones & Additives, a global leader and producer of ketones and carbinols at its facilities in Institute, West Virginia. This business was acquired from The Dow Chemical Company in 2019, and it serves the coatings, industrial and automotive lubricants, and adhesives industries.
    • ALTIVIA Oxide Chemicals specializes in custom production of various chemical intermediates serving surfactant, lubricant, and fuel additives markets. The production facility in Crosby, Texas, includes 31 reactors and distillation trains with ethoxylation, propoxylation and a range of organic reaction capabilities.

    For more information contact:

    Kelly Kimberly

    +1.713.822.7538

    [email protected] 

    Dean Hale, Corporate Engineering Manager

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/altivia-appoints-scott-barnum-as-director-of-manufacturing-and-dean-hale-as-corporate-engineering-manager-302110654.html

    SOURCE ALTIVIA

    Get the next $DOW alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DOW
    $PFE

    CompanyDatePrice TargetRatingAnalyst
    Pfizer Inc.
    $PFE
    4/22/2025$24.00Neutral
    Cantor Fitzgerald
    Dow Inc.
    $DOW
    4/15/2025$28.00Buy → Underperform
    BofA Securities
    Dow Inc.
    $DOW
    4/4/2025$31.00Overweight → Neutral
    Analyst
    Dow Inc.
    $DOW
    1/7/2025$60.00 → $53.00Overweight → Neutral
    Piper Sandler
    Dow Inc.
    $DOW
    12/18/2024$56.00In-line → Outperform
    Evercore ISI
    Pfizer Inc.
    $PFE
    12/10/2024$29.00Neutral
    BofA Securities
    Pfizer Inc.
    $PFE
    11/15/2024$25.00Underperform
    Wolfe Research
    Pfizer Inc.
    $PFE
    10/25/2024$30.00Neutral
    Citigroup
    More analyst ratings

    $DOW
    $PFE
    SEC Filings

    See more
    • SEC Form 11-K filed by Pfizer Inc.

      11-K - PFIZER INC (0000078003) (Filer)

      6/16/25 4:12:32 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 11-K filed by Pfizer Inc.

      11-K - PFIZER INC (0000078003) (Filer)

      6/16/25 4:07:31 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-3ASR filed by Dow Inc.

      S-3ASR - DOW INC. (0001751788) (Filer)

      6/13/25 4:15:47 PM ET
      $DOW
      Major Chemicals
      Industrials

    $DOW
    $PFE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Blaylock Ronald E bought $499,072 worth of shares (19,457 units at $25.65), increasing direct ownership by 236% to 27,707 units (SEC Form 4)

      4 - PFIZER INC (0000078003) (Issuer)

      2/14/25 5:16:36 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Dial Debra L. bought $26,197 worth of shares (675 units at $38.81) (SEC Form 4)

      4 - DOW INC. (0001751788) (Issuer)

      2/11/25 4:15:26 PM ET
      $DOW
      Major Chemicals
      Industrials
    • Director Banister Gaurdie E. Jr. bought $299,932 worth of shares (7,339 units at $40.87) (SEC Form 4)

      4 - DOW INC. (0001751788) (Issuer)

      12/17/24 4:59:47 PM ET
      $DOW
      Major Chemicals
      Industrials

    $DOW
    $PFE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)

      PHILADELPHIA, June 12, 2025 (GLOBE NEWSWIRE) -- Berger Montague advises shareholders of Pfizer Inc. ("Pfizer" or the "Company") (NYSE:PFE) about an investigation into Pfizer's Board of Directors for potential breaches of fiduciary duties to Pfizer and its shareholders in connection with the Company's marketing and sale of Depo-Provera. Shareholders of PFIZER may learn more about this investigation by contacting Berger Montague: Radha Raghavan at [email protected] or (332) 271-8908, or Andrew Abramowitz at [email protected] or (215) 875-3015 or visit: https://investigations.bergermontague.com/pfizer/ Berger Montague's investigation is focused on whether Pfizer's Board of Directors breache

      6/12/25 3:11:00 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canadian court orders NOVA Chemicals to pay Dow an additional CAD$1.6 billion judgment

      MIDLAND, Mich., June 11, 2025 /PRNewswire/ -- The Court of King's Bench of Alberta, Canada has issued a judgment ordering NOVA Chemicals Corporation to pay Dow (NYSE:DOW) an additional amount of CAD$1.620 billion (equivalent to approximately USD$1.2 billion) in damages. The judgment, signed on June 10, 2025, relates to losses Dow incurred from the companies' jointly owned ethylene asset in Joffre, Alberta, Canada. The award includes interest to April 7, 2025, but excludes subsequent interest or legal costs. Payment is anticipated to occur in the fourth quarter of 2025. This la

      6/11/25 6:00:00 AM ET
      $DOW
      Major Chemicals
      Industrials
    • AM Best Affirms Credit Ratings of Blue Whale Re Ltd.

      AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of "a+" (Excellent) of Blue Whale Re Ltd. (Blue Whale) (Burlington, VT). The outlook of these Credit Ratings (ratings) is stable. The ratings reflect Blue Whale's balance sheet strength, which AM Best assesses as very strong, as well as its strong operating performance, neutral business profile and appropriate enterprise risk management (ERM). The ratings also reflect Blue Whale's function as the only captive insurer for Pfizer Inc. (Pfizer) (NYSE:PFE), a global pharmaceutical company. As Blue Whale insures or reinsures Pfizer's global property exposures, it plays a strategic and c

      6/6/25 1:26:00 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care